Mount Yale Investment Advisors LLC Reduces Holdings in Smith & Nephew plc (SNN)

Share on StockTwits

Mount Yale Investment Advisors LLC trimmed its position in Smith & Nephew plc (NYSE:SNN) by 53.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,742 shares of the medical equipment provider’s stock after selling 10,964 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Smith & Nephew were worth $366,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Eagle Asset Management Inc. boosted its stake in Smith & Nephew by 10.2% in the second quarter. Eagle Asset Management Inc. now owns 16,325 shares of the medical equipment provider’s stock valued at $612,000 after acquiring an additional 1,516 shares during the period. First Republic Investment Management Inc. boosted its stake in Smith & Nephew by 10.4% in the second quarter. First Republic Investment Management Inc. now owns 19,599 shares of the medical equipment provider’s stock valued at $736,000 after acquiring an additional 1,841 shares during the period. Thomas White International Ltd. boosted its stake in Smith & Nephew by 3.6% in the second quarter. Thomas White International Ltd. now owns 59,342 shares of the medical equipment provider’s stock valued at $2,227,000 after acquiring an additional 2,046 shares during the period. Crossmark Global Holdings Inc. boosted its stake in Smith & Nephew by 0.6% in the second quarter. Crossmark Global Holdings Inc. now owns 357,091 shares of the medical equipment provider’s stock valued at $13,402,000 after acquiring an additional 2,109 shares during the period. Finally, Raymond James & Associates boosted its stake in Smith & Nephew by 7.2% in the second quarter. Raymond James & Associates now owns 31,587 shares of the medical equipment provider’s stock valued at $1,185,000 after acquiring an additional 2,109 shares during the period. Institutional investors and hedge funds own 8.71% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Smith & Nephew from a “hold” rating to a “sell” rating in a report on Friday, October 5th. UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, August 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $42.00 price target on shares of Smith & Nephew in a report on Monday, August 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $41.00.

Shares of SNN traded up $0.17 during mid-day trading on Friday, reaching $34.56. 364,023 shares of the company’s stock traded hands, compared to its average volume of 615,332. Smith & Nephew plc has a 12 month low of $33.79 and a 12 month high of $39.85. The stock has a market cap of $16.22 billion, a PE ratio of 18.19, a price-to-earnings-growth ratio of 3.05 and a beta of 0.47. The company has a current ratio of 2.13, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Smith & Nephew Profile

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply